25 XP   0   0   10

Kancera AB (publ)
Buy, Hold or Sell?

Let's analyse Kancera together

PenkeI guess you are interested in Kancera AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kancera AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kancera AB (publ)

I send you an email if I find something interesting about Kancera AB (publ).

Quick analysis of Kancera (30 sec.)










What can you expect buying and holding a share of Kancera? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.57
Expected worth in 1 year
kr-0.14
How sure are you?
34.5%

+ What do you gain per year?

Total Gains per Share
kr-0.71
Return On Investment
-41.5%

For what price can you sell your share?

Current Price per Share
kr1.71
Expected price per share
kr1.502 - kr2.3150018548287
How sure are you?
50%

1. Valuation of Kancera (5 min.)




Live pricePrice per Share (EOD)

kr1.71

2. Growth of Kancera (5 min.)




Is Kancera growing?

Current yearPrevious yearGrowGrow %
How rich?$4.4m$9.3m-$2.7m-41.6%

How much money is Kancera making?

Current yearPrevious yearGrowGrow %
Making money-$1.5m-$1.2m-$291.5k-19.1%
Net Profit Margin-4,213.9%-15,288.1%--

How much money comes from the company's main activities?

3. Financial Health of Kancera (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#767 / 1031

Most Revenue
#691 / 1031

Most Profit
#289 / 1031

Most Efficient
#904 / 1031

What can you expect buying and holding a share of Kancera? (5 min.)

Welcome investor! Kancera's management wants to use your money to grow the business. In return you get a share of Kancera.

What can you expect buying and holding a share of Kancera?

First you should know what it really means to hold a share of Kancera. And how you can make/lose money.

Speculation

The Price per Share of Kancera is kr1.712. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kancera.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kancera, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.57. Based on the TTM, the Book Value Change Per Share is kr-0.18 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kancera.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.02-1.2%-0.02-1.1%-0.01-0.9%-0.01-0.9%-0.01-0.7%
Usd Book Value Change Per Share-0.02-1.2%-0.02-1.0%0.00-0.3%0.000.1%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.02-1.2%-0.02-1.0%0.00-0.3%0.000.1%0.000.1%
Usd Price Per Share0.44-0.38-0.47-0.43-0.36-
Price to Earnings Ratio-5.25--5.69--8.27--8.68--8.16-
Price-to-Total Gains Ratio-21.03--24.08--27.61--26.68--21.67-
Price to Book Ratio8.14-5.24-4.29-5.66-6.06-
Price-to-Total Gains Ratio-21.03--24.08--27.61--26.68--21.67-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.160928
Number of shares6213
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.00
Usd Total Gains Per Share-0.020.00
Gains per Quarter (6213 shares)-103.6811.57
Gains per Year (6213 shares)-414.7246.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-415-42504636
20-829-84009382
30-1244-12550139128
40-1659-16700185174
50-2074-20850231220
60-2488-25000278266
70-2903-29150324312
80-3318-33300370358
90-3732-37450417404
100-4147-41600463450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.029.00.00.0%0.029.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%7.013.00.035.0%10.019.00.034.5%10.019.00.034.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%7.013.00.035.0%10.019.00.034.5%10.019.00.034.5%

Fundamentals of Kancera

About Kancera AB (publ)

Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.

Fundamental data was last updated by Penke on 2024-03-19 16:27:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kancera AB (publ).

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kancera earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Kancera to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kancera AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-4,213.9%+4,213.9%
TTM-4,213.9%YOY-15,288.1%+11,074.2%
TTM-4,213.9%5Y-10,493.7%+6,279.8%
5Y-10,493.7%10Y-9,879.2%-614.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM-4,213.9%-202.3%-4,011.6%
YOY-15,288.1%-263.0%-15,025.1%
5Y-10,493.7%-452.4%-10,041.3%
10Y-9,879.2%-589.0%-9,290.2%
1.1.2. Return on Assets

Shows how efficient Kancera is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kancera to the Biotechnology industry mean.
  • -28.1% Return on Assets means that Kancera generated kr-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kancera AB (publ):

  • The MRQ is -28.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.1%TTM-19.6%-8.5%
TTM-19.6%YOY-11.8%-7.8%
TTM-19.6%5Y-19.8%+0.2%
5Y-19.8%10Y-20.0%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.1%-12.5%-15.6%
TTM-19.6%-12.2%-7.4%
YOY-11.8%-11.2%-0.6%
5Y-19.8%-13.3%-6.5%
10Y-20.0%-14.6%-5.4%
1.1.3. Return on Equity

Shows how efficient Kancera is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kancera to the Biotechnology industry mean.
  • -38.7% Return on Equity means Kancera generated kr-0.39 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kancera AB (publ):

  • The MRQ is -38.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -24.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-38.7%TTM-24.6%-14.2%
TTM-24.6%YOY-13.3%-11.2%
TTM-24.6%5Y-32.1%+7.6%
5Y-32.1%10Y-30.9%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.7%-16.0%-22.7%
TTM-24.6%-15.8%-8.8%
YOY-13.3%-13.9%+0.6%
5Y-32.1%-18.2%-13.9%
10Y-30.9%-19.1%-11.8%

1.2. Operating Efficiency of Kancera AB (publ).

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kancera is operating .

  • Measures how much profit Kancera makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kancera to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kancera AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-4,144.6%+4,144.6%
TTM-4,144.6%YOY-15,645.4%+11,500.8%
TTM-4,144.6%5Y-8,093.1%+3,948.4%
5Y-8,093.1%10Y-8,332.4%+239.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-4,144.6%-208.5%-3,936.1%
YOY-15,645.4%-280.2%-15,365.2%
5Y-8,093.1%-459.9%-7,633.2%
10Y-8,332.4%-596.9%-7,735.5%
1.2.2. Operating Ratio

Measures how efficient Kancera is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Kancera AB (publ):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM42.354-42.354
TTM42.354YOY153.788-111.434
TTM42.3545Y96.177-53.823
5Y96.17710Y94.051+2.126
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM42.3543.181+39.173
YOY153.7883.609+150.179
5Y96.1775.554+90.623
10Y94.0517.396+86.655

1.3. Liquidity of Kancera AB (publ).

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kancera is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.65 means the company has kr2.65 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Kancera AB (publ):

  • The MRQ is 2.650. The company is able to pay all its short-term debts. +1
  • The TTM is 4.468. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.650TTM4.468-1.818
TTM4.468YOY7.207-2.739
TTM4.4685Y5.513-1.045
5Y5.51310Y4.941+0.572
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6503.987-1.337
TTM4.4684.440+0.028
YOY7.2075.569+1.638
5Y5.5136.158-0.645
10Y4.9416.492-1.551
1.3.2. Quick Ratio

Measures if Kancera is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kancera to the Biotechnology industry mean.
  • A Quick Ratio of 2.65 means the company can pay off kr2.65 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kancera AB (publ):

  • The MRQ is 2.650. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.468. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.650TTM4.468-1.818
TTM4.468YOY7.207-2.739
TTM4.4685Y5.294-0.825
5Y5.29410Y3.703+1.591
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6503.653-1.003
TTM4.4684.158+0.310
YOY7.2075.515+1.692
5Y5.2946.012-0.718
10Y3.7036.206-2.503

1.4. Solvency of Kancera AB (publ).

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kancera assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kancera to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Kancera assets are financed with 27.4% credit (debt) and the remaining percentage (100% - 27.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kancera AB (publ):

  • The MRQ is 0.274. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.184. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.274TTM0.184+0.090
TTM0.184YOY0.113+0.071
TTM0.1845Y0.218-0.034
5Y0.21810Y0.230-0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2740.336-0.062
TTM0.1840.330-0.146
YOY0.1130.267-0.154
5Y0.2180.367-0.149
10Y0.2300.378-0.148
1.4.2. Debt to Equity Ratio

Measures if Kancera is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kancera to the Biotechnology industry mean.
  • A Debt to Equity ratio of 37.7% means that company has kr0.38 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kancera AB (publ):

  • The MRQ is 0.377. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.231. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.377TTM0.231+0.146
TTM0.231YOY0.127+0.104
TTM0.2315Y0.361-0.130
5Y0.36110Y0.359+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3770.376+0.001
TTM0.2310.398-0.167
YOY0.1270.334-0.207
5Y0.3610.431-0.070
10Y0.3590.476-0.117

2. Market Valuation of Kancera AB (publ)

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Kancera generates.

  • Above 15 is considered overpriced but always compare Kancera to the Biotechnology industry mean.
  • A PE ratio of -5.25 means the investor is paying kr-5.25 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kancera AB (publ):

  • The EOD is -1.934. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.255. Based on the earnings, the company is expensive. -2
  • The TTM is -5.694. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.934MRQ-5.255+3.321
MRQ-5.255TTM-5.694+0.440
TTM-5.694YOY-8.270+2.576
TTM-5.6945Y-8.681+2.986
5Y-8.68110Y-8.157-0.524
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.934-2.697+0.763
MRQ-5.255-2.422-2.833
TTM-5.694-2.709-2.985
YOY-8.270-4.116-4.154
5Y-8.681-6.257-2.424
10Y-8.157-6.478-1.679
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kancera AB (publ):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-5.055+5.055
TTM-5.055YOY-9.165+4.109
TTM-5.0555Y-17.530+12.475
5Y-17.53010Y-14.771-2.760
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--2.939+2.939
TTM-5.055-3.486-1.569
YOY-9.165-5.592-3.573
5Y-17.530-8.464-9.066
10Y-14.771-8.872-5.899
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kancera is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 8.14 means the investor is paying kr8.14 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Kancera AB (publ):

  • The EOD is 2.997. Based on the equity, the company is underpriced. +1
  • The MRQ is 8.144. Based on the equity, the company is overpriced. -1
  • The TTM is 5.235. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.997MRQ8.144-5.147
MRQ8.144TTM5.235+2.908
TTM5.235YOY4.292+0.943
TTM5.2355Y5.660-0.424
5Y5.66010Y6.060-0.400
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.9972.198+0.799
MRQ8.1442.042+6.102
TTM5.2352.121+3.114
YOY4.2922.907+1.385
5Y5.6603.682+1.978
10Y6.0604.114+1.946
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Kancera AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.221-0.178-20%-0.048-79%0.020-1216%0.020-1223%
Book Value Per Share--0.5710.839-32%1.188-52%0.868-34%0.690-17%
Current Ratio--2.6504.468-41%7.207-63%5.513-52%4.941-46%
Debt To Asset Ratio--0.2740.184+49%0.113+143%0.218+26%0.230+19%
Debt To Equity Ratio--0.3770.231+63%0.127+197%0.361+4%0.359+5%
Dividend Per Share----0%-0%-0%-0%
Eps---0.221-0.194-12%-0.157-29%-0.155-30%-0.130-41%
Gross Profit Margin--1.0001.018-2%1.037-4%1.011-1%1.008-1%
Market Cap142838487.552-172%388176252.318335009479.126+16%419779954.685-8%399526306.626-3%371130134.862+5%
Net Profit Margin----42.1390%-152.8810%-104.9370%-98.7920%
Operating Margin----41.4460%-156.4540%-80.9310%-83.3240%
Operating Ratio---42.354-100%153.788-100%96.177-100%94.051-100%
Pb Ratio2.997-172%8.1445.235+56%4.292+90%5.660+44%6.060+34%
Pe Ratio-1.934+63%-5.255-5.694+8%-8.270+57%-8.681+65%-8.157+55%
Price Per Share1.712-172%4.6534.015+16%5.031-8%4.599+1%3.789+23%
Price To Free Cash Flow Ratio----5.0550%-9.1650%-17.5300%-14.7710%
Price To Total Gains Ratio-7.740+63%-21.035-24.081+14%-27.610+31%-26.676+27%-21.669+3%
Quick Ratio--2.6504.468-41%7.207-63%5.294-50%3.703-28%
Return On Assets---0.281-0.196-30%-0.118-58%-0.198-30%-0.200-29%
Return On Equity---0.387-0.246-37%-0.133-66%-0.321-17%-0.309-20%
Total Gains Per Share---0.221-0.178-20%-0.048-79%0.020-1216%0.020-1223%
Usd Book Value--4480510.0006581128.000-32%9317115.500-52%6993087.700-36%6165810.069-27%
Usd Book Value Change Per Share---0.021-0.017-20%-0.004-79%0.002-1216%0.002-1223%
Usd Book Value Per Share--0.0540.079-32%0.112-52%0.082-34%0.065-17%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.021-0.018-12%-0.015-29%-0.015-30%-0.012-41%
Usd Free Cash Flow----999854.5000%-1106685.5000%-1042605.7000%-1050845.4480%
Usd Market Cap13426817.830-172%36488567.71831490891.038+16%39459315.740-8%37555472.823-3%34886232.677+5%
Usd Price Per Share0.161-172%0.4370.377+16%0.473-8%0.432+1%0.356+23%
Usd Profit---1735992.000-1524891.500-12%-1233374.000-29%-1374406.900-21%-1299786.621-25%
Usd Revenue---13912.000-100%12361.000-100%29854.400-100%24433.517-100%
Usd Total Gains Per Share---0.021-0.017-20%-0.004-79%0.002-1216%0.002-1223%
 EOD+3 -4MRQTTM+5 -21YOY+3 -235Y+3 -2310Y+5 -21

3.2. Fundamental Score

Let's check the fundamental score of Kancera AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.934
Price to Book Ratio (EOD)Between0-12.997
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.650
Current Ratio (MRQ)Greater than12.650
Debt to Asset Ratio (MRQ)Less than10.274
Debt to Equity Ratio (MRQ)Less than10.377
Return on Equity (MRQ)Greater than0.15-0.387
Return on Assets (MRQ)Greater than0.05-0.281
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Kancera AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.735
Ma 20Greater thanMa 501.822
Ma 50Greater thanMa 1002.962
Ma 100Greater thanMa 2003.613
OpenGreater thanClose1.730
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets65,643
Total Liabilities17,978
Total Stockholder Equity47,665
 As reported
Total Liabilities 17,978
Total Stockholder Equity+ 47,665
Total Assets = 65,643

Assets

Total Assets65,643
Total Current Assets47,642
Long-term Assets18,001
Total Current Assets
Cash And Cash Equivalents 45,692
Net Receivables 1,950
Total Current Assets  (as reported)47,642
Total Current Assets  (calculated)47,642
+/-0
Long-term Assets
Other Assets 0
Long-term Assets  (as reported)18,001
Long-term Assets  (calculated)0
+/- 18,001

Liabilities & Shareholders' Equity

Total Current Liabilities17,978
Long-term Liabilities0
Total Stockholder Equity47,665
Total Current Liabilities
Other Current Liabilities 17,978
Total Current Liabilities  (as reported)17,978
Total Current Liabilities  (calculated)17,978
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock7,921
Retained Earnings -4,889
Other Stockholders Equity 44,633
Total Stockholder Equity (as reported)47,665
Total Stockholder Equity (calculated)47,665
+/-0
Other
Cash and Short Term Investments 45,692
Common Stock Shares Outstanding 83,434
Liabilities and Stockholders Equity 65,643
Net Debt -45,692
Net Working Capital 29,664



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
73,032
63,934
76,087
68,995
51,225
40,638
75,052
58,787
45,533
42,451
36,344
36,346
44,353
56,219
92,077
96,644
83,102
77,384
154,136
145,834
133,640
122,934
108,810
94,273
120,738
104,734
91,435
78,320
65,643
65,64378,32091,435104,734120,73894,273108,810122,934133,640145,834154,13677,38483,10296,64492,07756,21944,35336,34636,34442,45145,53358,78775,05240,63851,22568,99576,08763,93473,032
   > Total Current Assets 
65,004
56,200
62,646
49,847
32,593
22,263
56,840
40,642
27,422
18,053
12,554
7,164
15,821
28,262
64,727
71,448
61,174
55,546
132,388
124,177
111,799
101,416
87,382
72,935
99,490
83,576
70,367
60,319
47,642
47,64260,31970,36783,57699,49072,93587,382101,416111,799124,177132,38855,54661,17471,44864,72728,26215,8217,16412,55418,05327,42240,64256,84022,26332,59349,84762,64656,20065,004
       Cash And Cash Equivalents 
57,759
48,323
54,101
46,079
27,775
17,958
52,703
34,838
21,023
15,193
8,880
3,896
11,848
3,215
56,443
47,567
55,008
45,413
129,944
118,697
106,521
96,727
82,286
68,221
95,149
76,131
66,972
58,220
45,692
45,69258,22066,97276,13195,14968,22182,28696,727106,521118,697129,94445,41355,00847,56756,4433,21511,8483,8968,88015,19321,02334,83852,70317,95827,77546,07954,10148,32357,759
       Net Receivables 
860
1,780
1,893
3,054
1,519
2,360
2,300
3,522
1,697
2,860
3,674
3,268
848
25,047
8,284
23,881
1,100
10,133
2,444
5,480
5,278
4,689
5,096
4,714
4,341
7,445
3,395
2,099
1,950
1,9502,0993,3957,4454,3414,7145,0964,6895,2785,4802,44410,1331,10023,8818,28425,0478483,2683,6742,8601,6973,5222,3002,3601,5193,0541,8931,780860
       Inventory 
5,760
6,097
6,652
714
1,580
1,945
1,837
2,282
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000002,2821,8371,9451,5807146,6526,0975,760
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
24,398
23,790
29,182
28,532
0
27,350
25,196
21,928
21,838
21,748
21,657
21,608
21,518
21,428
21,338
21,248
21,158
21,068
18,001
18,001
18,00118,00121,06821,15821,24821,33821,42821,51821,60821,65721,74821,83821,92825,19627,350028,53229,18223,79024,398000000000
       Property Plant Equipment 
2,028
1,734
1,441
1,148
632
375
212
145
111
6,398
5,790
5,182
4,531
3,956
3,349
1,195
927
837
747
657
607
517
427
337
247
157
67
0
0
00671572473374275176076577478379271,1953,3493,9564,5315,1825,7906,3981111452123756321,1481,4411,7342,028
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001000000000000
       Intangible Assets 
6,000
6,000
12,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
24,000
24,000
24,000
24,000
24,000
21,000
21,000
21,000
21,000
21,000
21,000
21,000
21,000
21,000
21,000
21,000
18,000
0
018,00021,00021,00021,00021,00021,00021,00021,00021,00021,00021,00021,00024,00024,00024,00024,00024,00018,00018,00018,00018,00018,00018,00018,00018,00012,0006,0006,000
       Other Assets 
0
0
0
0
0
0
0
0
18,000
18,000
18,000
24,000
0
0
0
24,000
21,000
0
21,000
20,999
-1
0
0
21,000
0
21,000
0
0
0
00021,000021,00000-120,99921,000021,00024,00000024,00018,00018,00018,00000000000
> Total Liabilities 
13,507
13,957
15,995
24,223
12,514
14,399
18,854
13,331
12,176
17,050
17,073
12,738
26,934
31,184
14,812
11,644
10,819
11,064
10,425
12,547
10,870
12,405
13,843
10,208
13,826
15,321
14,584
12,201
17,978
17,97812,20114,58415,32113,82610,20813,84312,40510,87012,54710,42511,06410,81911,64414,81231,18426,93412,73817,07317,05012,17613,33118,85414,39912,51424,22315,99513,95713,507
   > Total Current Liabilities 
10,645
11,102
13,101
21,361
9,568
11,320
18,854
10,252
11,521
8,568
8,526
4,143
26,355
30,750
14,378
10,919
9,842
10,622
9,983
12,105
10,429
12,405
13,843
10,208
13,826
15,321
14,584
12,201
17,978
17,97812,20114,58415,32113,82610,20813,84312,40510,42912,1059,98310,6229,84210,91914,37830,75026,3554,1438,5268,56811,52110,25218,85411,3209,56821,36113,10111,10210,645
       Short-term Debt 
2,862
2,855
2,894
2,862
2,946
3,079
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000003,0792,9462,8622,8942,8552,862
       Short Long Term Debt 
2,862
2,855
2,894
2,862
2,946
3,079
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000003,0792,9462,8622,8942,8552,862
       Accounts payable 
2,125
0
0
0
3,423
0
0
0
5,999
0
0
0
2,171
0
0
0
2,408
0
0
0
3,600
0
0
0
3,327
0
0
0
0
00003,3270003,6000002,4080002,1710005,9990003,4230002,125
       Other Current Liabilities 
5,892
11,102
13,101
21,361
2,736
11,320
18,854
10,252
3,108
8,568
8,526
4,143
4,890
30,750
14,378
10,919
3,240
10,622
9,983
12,105
10,429
12,405
13,843
10,208
10,499
15,321
14,584
12,201
17,978
17,97812,20114,58415,32110,49910,20813,84312,40510,42912,1059,98310,6223,24010,91914,37830,7504,8904,1438,5268,5683,10810,25218,85411,3202,73621,36113,10111,1025,892
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
8,482
8,547
8,595
579
0
434
725
977
442
442
442
441
0
0
0
0
0
0
0
0
0000000044144244244297772543405798,5958,5478,482000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
442
442
442
-1
0
0
0
0
0
0
0
0
00000000-144244244200000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
18,000
18,000
18,000
24,000
0
0
0
24,000
21,000
0
21,000
21,000
21,000
0
0
21,000
0
21,000
0
0
0
00021,000021,0000021,00021,00021,000021,00024,00000024,00018,00018,00018,00000000000
> Total Stockholder Equity
59,525
49,977
60,092
44,772
38,711
26,239
56,198
45,456
33,357
25,401
19,271
23,608
17,419
25,035
77,265
85,000
72,283
66,320
143,711
133,287
122,770
110,529
94,966
84,063
106,911
89,412
76,850
66,117
47,665
47,66566,11776,85089,412106,91184,06394,966110,529122,770133,287143,71166,32072,28385,00077,26525,03517,41923,60819,27125,40133,35745,45656,19826,23938,71144,77260,09249,97759,525
   Common Stock
10,957
10,957
12,162
12,219
12,386
12,386
15,878
15,879
15,879
15,879
16,486
17,486
17,485
17,486
36,367
36,367
39,516
39,516
46,485
46,582
46,786
46,786
46,786
46,786
66,273
66,273
67,921
67,921
7,921
7,92167,92167,92166,27366,27346,78646,78646,78646,78646,58246,48539,51639,51636,36736,36717,48617,48517,48616,48615,87915,87915,87915,87812,38612,38612,21912,16210,95710,957
   Retained Earnings Total Equity00000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
36,029
19,219
66,369
3,149
72,283
3,157
124,571
233
-1
110,529
75,750
75,750
401,579
40,638
44,617
44,617
44,633
44,63344,61744,61740,638401,57975,75075,750110,529-1233124,5713,15772,2833,14966,36919,21936,029000000000000



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue619
Cost of Revenue-3,000
Gross Profit-3,000-2,381
 
Operating Income (+$)
Gross Profit-3,000
Operating Expense-63,077
Operating Income-66,077-66,077
 
Operating Expense (+$)
Research Development57,989
Selling General Administrative8,120
Selling And Marketing Expenses0
Operating Expense63,07766,109
 
Net Interest Income (+$)
Interest Income0
Interest Expense-373
Other Finance Cost-402
Net Interest Income29
 
Pretax Income (+$)
Operating Income-66,077
Net Interest Income29
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-64,889-67,265
EBIT - interestExpense = -66,450
-64,889
-64,516
Interest Expense373
Earnings Before Interest and Taxes (EBIT)-66,077-64,516
Earnings Before Interest and Taxes (EBITDA)-63,077
 
After tax Income (+$)
Income Before Tax-64,889
Tax Provision-0
Net Income From Continuing Ops-60,432-64,889
Net Income-64,889
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses66,077
Total Other Income/Expenses Net1,188-29
 

Technical Analysis of Kancera
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kancera. The general trend of Kancera is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kancera's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kancera AB (publ).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.812 < 2.22 < 2.3150018548287.

The bearish price targets are: 1.502.

Tweet this
Kancera AB (publ) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kancera AB (publ). The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kancera AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kancera AB (publ). The current macd is -0.34122204.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kancera price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kancera. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kancera price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Kancera AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartKancera AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kancera AB (publ). The current adx is 31.68.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Kancera shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Kancera AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kancera AB (publ). The current sar is 1.5296408.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Kancera AB (publ) Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kancera AB (publ). The current rsi is 34.73. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Kancera AB (publ) Daily Relative Strength Index (RSI) ChartKancera AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kancera AB (publ). The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kancera price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Kancera AB (publ) Daily Stochastic Oscillator ChartKancera AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kancera AB (publ). The current cci is -103.91980551.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Kancera AB (publ) Daily Commodity Channel Index (CCI) ChartKancera AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kancera AB (publ). The current cmo is -21.03322943.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kancera AB (publ) Daily Chande Momentum Oscillator (CMO) ChartKancera AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kancera AB (publ). The current willr is -69.91404011.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Kancera is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Kancera AB (publ) Daily Williams %R ChartKancera AB (publ) Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kancera AB (publ).

Kancera AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kancera AB (publ). The current atr is 0.20844247.

Kancera AB (publ) Daily Average True Range (ATR) ChartKancera AB (publ) Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kancera AB (publ). The current obv is -1,115,332.

Kancera AB (publ) Daily On-Balance Volume (OBV) ChartKancera AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kancera AB (publ). The current mfi is 34.45.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Kancera AB (publ) Daily Money Flow Index (MFI) ChartKancera AB (publ) Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kancera AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Kancera AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kancera AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.735
Ma 20Greater thanMa 501.822
Ma 50Greater thanMa 1002.962
Ma 100Greater thanMa 2003.613
OpenGreater thanClose1.730
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kancera with someone you think should read this too:
  • Are you bullish or bearish on Kancera? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kancera? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kancera AB (publ)

I send you an email if I find something interesting about Kancera AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about Kancera AB (publ).

Receive notifications about Kancera AB (publ) in your mailbox!